AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01991379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Following informed consent, the first 20 mandatory patients, except for patients who have already been treated with imatinib prior to consent, and subsequent voluntary patients enrolled on the phase II portion of the trial will undergo research biopsies. Patients should hold both imatinib and MEK162 doses on the day they undergo a biopsy.
Study NCT03941236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasiglucagon
Description: Glucagon analog
Study NCT03676153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-provided guidance
Description: Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
Study NCT03676153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrative medicine treatment program
Description: Integrative medicine treatment program
Study NCT03676153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative medicine treatment program
Description: Integrative medicine treatment program
Study NCT04802980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1T
Description: HB002.1T is a vascular endothelial growth factor receptor decoy
Study NCT03679949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone, 2.5 mg
Study NCT04802980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is an anti-tumor drug
Study NCT00422006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clamp euglycemic - hyperglycemic
Description: clamp euglycemic-hyperglycemic
Study NCT00422006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: diet
Study NCT04802980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is an anti-tumor drug
Study NCT04802980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an anti-tumor drug
Study NCT04802980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is an anti-tumor drug
Study NCT04802980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is an anti-tumor drug
Study NCT04802980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an anti-tumor drug
Study NCT01875367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Injectable Solution
Description: Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
Study NCT01875367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Injectable Product
Description: Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
Study NCT01875367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Injection
Description: Powder for concentrate for solution for infusion. 1 cycle
Study NCT02017236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volitinib
Description: 600mg Volitinib ,single dose,oral
Study NCT02258867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous injection
Study NCT00419276 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ambulatory continuous femoral nerve block for 100 hours
Description: Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
Study NCT05231057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Mat, Pilates band or elastic bands, and Pilate's ball
Study NCT05231057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy program
Description: pain relief, increasing flexibility, and mobility, improving muscle strength
Study NCT02258867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Description: Solution for subcutaneous injection
Study NCT02120157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy administration
Study NCT02120157 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TBI
Description: Radiation Therapy
Study NCT02120157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Chemotherapy Administered
Study NCT02120157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unmanipulated Bone Marrow
Description: Bone Marrow Transplant
Study NCT02120157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppressive Drug Administered
Study NCT02120157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Immunosuppressive Drug Administered
Study NCT03228433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-418
Description: TAK-418 Capsule.
Study NCT03178812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS with fine-needle aspiration of pancreatic cyst
Description: EUS with fine-needle aspiration
Study NCT03178812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Blood test
Description: Laboratory Blood Test
Study NCT03354702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic
Description: Aerobic exercise Patients performs 8 sessions of aerobic exercise (walking / running),with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
Study NCT03354702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching Patients performs 8 sessions of stretching, with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
Study NCT00441103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif® New Formulation (IFN-beta-1a, RNF)
Description: RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
Study NCT00441103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously three times a week for 16 weeks.
Study NCT00441103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rebif® New Formulation (IFN-beta-1a, RNF)
Description: RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
Study NCT04095754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head-Up Position
Description: Anti-Trendelenburg Position
Study NCT04095754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1
Study NCT04095754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1
Study NCT04095754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Induction and maintenance of anaesthesia
Description: Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim.
Study NCT04095754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction and maintenance of anaesthesia
Description: Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim.
Study NCT01059266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PURETHAL Grasses, 20.000 AUM/ml
Description: subcutaneous injections of increasing doses according to the described regimen
Study NCT01309841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 12.5 mg oral tablet once daily
Study NCT01309841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg oral tablet once daily
Study NCT01309841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet once daily
Study NCT04597281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The intervention group, will receive education on Mediterranean lifestyle (Mediterranean diet and physical activity promotion), combined with the provision of extra-virgin olive oil and fish, in order to be consumed at least 3 times per week. Physical activity sessions with a physical activity monitor will also be offered for free to the children (2 sessions of 60 minutes of moderate-vigorous physical activity, per week)
Study NCT00280150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00280150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00280150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00280150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00280150 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Given 5 days a week for 7 weeks
Study NCT02900963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: weekly assessment of patient's weight
Description: Biological assessment to determine biological and inflammatory status Quality of life questionary
Study NCT02782494 — intervention group
Intervention type: OTHER
Intervention: Examination of latent TB by QuantiFERON-TB
Description: Examination of latent TB by QuantiFERON-TB both QFT-plus QFT-GIT
Study NCT02996045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Description: A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-6, and scans scored 7-8 for which an alternative scan scored 8-9 exists.~This screen will show the appropriateness score of the original scan order, and will display up to 7 alternative scans that are scored >4 and greater than or equal to the original score for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.
Study NCT01941940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.
Study NCT01941940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
Study NCT00492765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a
Description: dosage and frequency as per label
Study NCT00492765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-beta-1a
Description: dosage and frequency as per label
Study NCT00492765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: dosage and frequency as per Biogen Idec protocol
Study NCT00492765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosage and frequency the same as simvastatin as per Biogen Idec Protocol
Study NCT02993692 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Direct laryngoscopy and fiberoptic bronchoscopy
Description: These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.
Study NCT00472121 — intervention group
Intervention type: DEVICE
Intervention: TOF-Watch SX (neuromuscular monitor)
Description: The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
Study NCT02287129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2
Study NCT02287129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2
Study NCT02287129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50 mg/m2
Study NCT03679949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC:CBD = ~ 1:0)
Description: Cannabis with high THC concentration and negligible CBD concentrations
Study NCT03679949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC:CBD = ~ 0:1)
Description: Cannabis with high CBD concentration and negligible THC concentrations
Study NCT03679949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC:CBD = ~ 1:1)
Description: Cannabis with equivalent CBD and THC concentrations
Study NCT03679949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
Study NCT03679949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
Study NCT01872091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy by immersion
Study NCT01872091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Study NCT04825119 — intervention group
Intervention type: DRUG
Intervention: Nusinersen
Description: Patients with SMA who will be treated with nusinersen will be included.
Study NCT00422006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsies for biological and genetic analyses
Description: biopsies for biological and genetic analyses
Study NCT03832894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol Valerate
Description: Oestradiol supplementation starting from day of trigger through out the luteal phase
Study NCT03832894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate
Description: Oestradiol supplementation starting from day of trigger through out the luteal phase
Study NCT03481608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lauric acid (coconut oil)
Description: A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.
Study NCT03481608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Lauric acid (olive oil)
Description: A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.
Study NCT00068601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Part of planned chemotherapy regimen
Study NCT00068601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Part of planned chemotherapy regimen
Study NCT00068601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given subcutaneously
Study NCT01061671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 40 mgms of simvastatin daily
Study NCT03228433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-418 Placebo
Description: TAK-418 placebo-matching capsules.
Study NCT01061671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo pill daily
Study NCT03320746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polar Loop 2 activity tracker
Description: The participants were instructed to aim to reach the daily activity goal, initially set at stage 1 as per the goals set by the trackers' manufacturer. The daily activity goal was based on user's typical daily activities, gender and age. The stage 1 daily activity goal corresponded to \~1h/day of jogging or \~2h/day of walking or \~7h/day household activities or a combination of these activities. The tracker gave an inactivity alert as a vibration and text it's time to move on the screen of the tracker if the user has been still for 55 minutes.
Study NCT02529839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation
Description: IMMUNOABLATIVE NONMYELOABLATIVE AUTOLOGOUS BONE MARROW TRANSPLANTATION on Day 0
Study NCT02529839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2 on days -6 through -3
Study NCT02529839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50mg/kg on days -5 through -4
Study NCT02529839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 3mg on day -3, 9mg on day -2, 12 mg on day -1
Study NCT03268993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Avmacol
Description: Avmacol is a dietary supplement available over the counter
Study NCT02717520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EQUIA Forte and Tetric EvoCeram
Description: GC cavity conditioner (20% polyacrylic acid) will be applied for 10 sec, rinsed and the cavity will be dried with a cotton pellet. EQUIA Forte will be prepared according to the manufacturer instructions, applied in bulk and compacted with a condenser. The self-curing restoration will be finished after hardening, approximately 2 min 30 sec after the start of the capsule mixing, using Arkansas stones under water cooling. EQUIA Forte Coat will be applied to the surfaces and light cured with D-light for 20 sec.~Enamel will be etched with 37% orthophosphoric acid for 10 sec. After the acid gel removal, the cavity will be carefully dried. The adhesive (Adhese 2, Ivoclar Vivadent) will be applied and light cured with D-light (1200 mW/cm2, slow mode) for 10 sec. The composite resin will be placed with an incremental technique (2 mm layers), and light-cured with D-light (20 sec). Restorations will be finished with fine diamond and carbide burs in slow and high-speed hand-piece and polished.
Study NCT03949530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDL-2965 Oral Capsule
Description: Investigational drug
Study NCT03949530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study NCT02489162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyotonPRO
Description: MyotonPRO measurements of the biomechanical properties of facial mimic muscles
Study NCT02489162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyotonPRO
Description: MyotonPRO measurements of the biomechanical properties of facial mimic muscles
Study NCT02489162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive electromyography (EMG)
Description: Gold standard technique for measuring muscle
Study NCT02489162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive electromyography (EMG)
Description: Gold standard technique for measuring muscle
Study NCT04119544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
Study NCT04948801 — intervention group
Intervention type: DRUG
Intervention: Epclusa (sofosbuvir and velpatasvir)
Description: Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
Study NCT05270876 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cochlear Implant and sound processor device fitting paradigm or diagnostic/measurement technique
Description: The investigational device will be a new device fitting paradigm or diagnostic/measurement technique implemented for use with the commercially available sound processor and implant.
Study NCT01911351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
Study NCT02793661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenalGuard
Description: Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.